WIPO Arbitration and Mediation Center ADMINISTRATIVE PANEL DECISION Sanofi v. WhoisGuard, Inc. / Daniel Kobelau Case No. D2019-0717 1. The Parties

Complainant is Sanofi of Paris, France, represented by Selarl Marchais & Associés, France.

Respondent is WhoisGuard, Inc. of Panama / Daniel Kobelau of Moscow, Russian Federation.1 2. The Domain Name and Registrar

The disputed domain name is registered with NameCheap, Inc. (the “Registrar”). 3. Procedural History

The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on March 29, 2019. On March 29, 2019, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain name. On March 29, 2019, the Registrar transmitted by email to the Center its verification response disclosing registrant and contact information for the disputed domain name which differed from the named Respondent and contact information in the Complaint. The Center sent an email communication to Complainant on April 1, 2019, providing the registrant and contact information disclosed by the Registrar, and inviting Complainant to submit an amendment to the Complaint. Complainant filed an amendment to the Complaint on April 4, 2019.

The Center verified that the Complaint together with the amendment to the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).

In accordance with the Rules, paragraphs 2 and 4, the Center formally notified Respondent of the Complaint, and the proceedings commenced on April 9, 2019. In accordance with the Rules, paragraph 5, the due date for the Response was April 29, 2019. Respondent did not submit any Response. Accordingly, the Center notified Respondent’s default on April 30, 2019.

The Center appointed Stephanie G. Hartung as the sole panelist in this matter on May 6, 2019. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7. 4. Factual Background

Complainant is domiciled in France and ranks among the world’s largest multinational pharmaceutical companies offering a wide range of prescription products, including “Plavix”.

Complainant has provided evidence that it is the registered owner of numerous trademarks relating to the designation “Plavix”, including, inter alia, the following:

- International trademark (word/device mark) PLAVIX, World Intellectual Property Organization (WIPO), Registration No.: 613041, Registration Date: December 27, 1993, with protection also for the territory of the Russian Federation, Status: active.
- European Union trademark (word mark) PLAVIX, European Intellectual Property Office (EUIPO), Registration No.: 002236578, Registration Date: April 18, 2002, Status: active.

Complainant, furthermore, has evidenced to be the owner of various domain names reflecting its PLAVIX trademark, e.g. the domain name which was first registered on March 26, 1998.

Respondent, who according to the WhoIs information for the disputed domain name is residing in Moscow, the Russian Federation, registered the disputed domain name on March 16, 2019. As of the time of the rendering of this decision, the disputed domain name resolves to a website at “www.” headed “ONLINE MED INFO CENTER” with hyperlinks to a variety of third parties’ websites in the online pharmacy business offering Plavix as well as other pharmaceutical products.

Complainant requests that the disputed domain name be transferred to Complainant. 5. Parties’ Contentions A. Complainant

Complainant contends to enjoy worldwide recognition on the pharmaceutical market, its Plavix product is available in over 115 countries worldwide, thus being one of the world’s 10 leading medicines.

Complainant submits that the disputed domain name is at least confusingly similar to Complainant’s PLAVIX trademark as it reproduces the latter in its entirety. Moreover, Complainant asserts that Respondent has no rights or legitimate interests in respect of the disputed domain name since (1) Complainant has never licensed or otherwise authorized Respondent to use its PLAVIX trademark or to register domain names including the very same and there is no relationship between the parties whatsoever, (2) Respondent has not used the disputed domain name in connection with a bona fide offering of goods or services, but on the contrary to run a website displaying the Plavix product along with false, inaccurate and misleading information and redirecting users via hyperlinks to a variety of